“We are very pleased to have Daiichi Sankyo make their studies available for sharing on the Vivli platform,” said Rebecca Li, Vivli Executive Director. “Our aspiration for Vivli is to act as a bridge across all stakeholders so that their studies can be requested and analyzed on the platform to further scientific discovery and I am delighted to have Daiichi Sankyo join us in partnership such that together we can further data sharing.”
Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.
In joining Vivli, Daiichi Sankyo demonstrates their strong commitment to clinical trial data sharing, to promote transparency and drive new discoveries.
“Patients, caregivers and healthcare providers expect and deserve maximum possible transparency from Daiichi Sankyo when it comes to our research and medicines,” says Marielle Cohard-Radice, Executive Vice President, Global Head of Development Operations at Daiichi Sankyo. “Participating in such data sharing platforms as the Vivli solution, which protects patient privacy while fostering forward progress in medicine, is an example of how we stay true to our three core values of innovation, integrity and accountability.
For more information about how Daiichi Sankyo shares data on Vivli, please visit their Member page. For additional information about Membership in Vivli, learn more here.